Opko Health, Inc. Adds to Growing Technology Portfolio Through Strategic Investment in Biotechnology Company Engaged in the Development of a New Generation of Antibodies
10/10/2013 12:57:03 PM
MIAMI--(BUSINESS WIRE)--OPKO Health, Inc. (NYSE: OPK) has agreed to make an investment in Zebra Biologics, Inc. (“Zebra”), a privately held biotechnology company focused on the discovery and development of biosuperior antibody therapeutics and complex drug targets. Zebra’s patented platform is an advanced version of a core technology that underlies the discovery and commercial success of AbbVie Inc.’s Humira™, developed by Richard Lerner, M.D., at The Scripps Research Institute. The technology allows for the selection of antibodies for function rather than through simple binding. Zebra has already developed an early pre-clinical pipeline of candidate antibodies with significant commercial potential in regulating diabetes and obesity, cancer, and treatment of neurological disease.
Help employers find you! Check out all the jobs and post your resume.
comments powered by